We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASS icon
76
908 Devices
MASS
$406M
$6.1M 0.35%
296,288
– –
MIST icon
77
Milestone Pharmaceuticals
MIST
$147M
$6.07M 0.35%
987,411
– –
GKOS icon
78
CALL
Glaukos
GKOS
$10.8B
$5.91M 0.34%
130,000
-738,100
-85% -$35M
WBA
79
PUT
DELISTED
Walgreens Boots Alliance
WBA
$5.68M 0.33%
+150,000
New +$6.45M
IRTC icon
80
iRhythm Holdings
IRTC
$4.04B
$5.4M 0.31%
+50,000
New +$6.62M
HSIC icon
81
PUT
Henry Schein
HSIC
$10B
$5.37M 0.31%
+70,000
New +$5.87M
EXAS
82
CALL
DELISTED
Exact Sciences
EXAS
$5.32M 0.31%
135,000
– –
ZBH icon
83
PUT
Zimmer Biomet
ZBH
$18.3B
$5.25M 0.31%
+50,000
New +$5.93M
RCM
84
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.23M 0.3%
249,732
+61,277
+33% +$1.39M
PRVA icon
85
Privia Health
PRVA
$2.74B
$5.19M 0.3%
178,255
-61,945
-26% -$1.57M
AGL icon
86
Agilon Health
AGL
$1.49B
$5.15M 0.3%
9,444
+7,644
+425% +$3.87M
CTKB icon
87
Cytek Biosciences
CTKB
$616M
$5.12M 0.3%
477,164
+52,587
+12% +$523K
KIDS icon
88
PUT
OrthoPediatrics
KIDS
$640M
$4.96M 0.29%
115,000
+60,000
+109% +$2.74M
COR icon
89
PUT
Cencora
COR
$61.4B
$4.95M 0.29%
+35,000
New +$5.35M
SDGR icon
90
CALL
Schrodinger
SDGR
$1.39B
$4.89M 0.28%
185,000
– –
AVTR icon
91
Avantor
AVTR
$9.27B
$4.82M 0.28%
+155,000
New +$4.84M
VRTX icon
92
Vertex Pharmaceuticals
VRTX
$134B
$4.72M 0.27%
16,763
-67,294
-80% -$18M
INMD icon
93
PUT
InMode
INMD
$873M
$4.71M 0.27%
210,000
+126,000
+150% +$3.31M
ATRC icon
94
AtriCure
ATRC
$2.17B
$4.36M 0.25%
106,615
-230,000
-68% -$10.9M
PHG icon
95
PUT
Philips
PHG
$26.2B
$4.31M 0.25%
+233,574
New +$5.03M
DNA icon
96
PUT
Ginkgo Bioworks
DNA
$499M
$4.17M 0.24%
43,750
+6,250
+17% +$762K
BVS icon
97
Bioventus
BVS
$1.15B
$4.09M 0.24%
599,080
+43,170
+8% +$440K
RGEN icon
98
PUT
Repligen
RGEN
$9.36B
$4.06M 0.24%
+25,000
New +$3.95M
TGTX icon
99
TG Therapeutics
TGTX
$7.66B
$4.04M 0.23%
950,813
+622,626
+190% +$3.89M
TVTX icon
100
Travere Therapeutics
TVTX
$5.85B
$4.03M 0.23%
166,201
+55,976
+51% +$1.41M
2 3
4
5 6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.